Capmatinib monotherapy (GEOMETRY mono-1) — MET ex14 NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CAPMATINIB |
|---|
| ID | REG-CAPMATINIB-NSCLC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-GEOMETRY-WOLF-2020 SRC-NCCN-NSCLC-2025 |
Notes
GEOMETRY mono-1: MET ex14 1L ORR 68%, mPFS 12.4 mo; pretreated ORR 41%, mPFS 5.4 mo. Approved for MET ex14 NSCLC any line. CNS activity demonstrated. Tepotinib (VISION) once-daily alternative with similar efficacy; choice driven by tolerability (capmatinib less edema, but BID burden).
Used By
Indication
IND-NSCLC-2L-MET-AMP-CAPMATINIB- IND-NSCLC-2L-MET-AMP-CAPMATINIBIND-NSCLC-2L-MET-EX14-CAPMATINIB- IND-NSCLC-2L-MET-EX14-CAPMATINIBIND-NSCLC-MET-EX14-1L-CAPMATINIB- IND-NSCLC-MET-EX14-1L-CAPMATINIB